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Abstract
Although platinum-based drugs are widely used chemotherapeutics
for cancer treatment, the determinants of tumor cell responsiveness
remain poorly understood. We show that the loss of subunits LRRC8A
and LRRC8D of the heteromeric LRRC8 volume-regulated anion
channels (VRACs) increased resistance to clinically relevant cisplatin/
carboplatin concentrations. Under isotonic conditions, about 50%
of cisplatin uptake depended on LRRC8A and LRRC8D, but neither on
LRRC8C nor on LRRC8E. Cell swelling strongly enhanced LRRC8-
dependent cisplatin uptake, bolstering the notion that cisplatin enters
cells through VRAC. LRRC8A disruption also suppressed drug-induced
apoptosis independently from drug uptake, possibly by impairing
VRAC-dependent apoptotic cell volume decrease. Hence, by mediating
cisplatin uptake and facilitating apoptosis, VRAC plays a dual role in
the cellular drug response. Incorporation of the LRRC8D subunit into
VRAC substantially increased its permeability for cisplatin and the
cellular osmolyte taurine, indicating that LRRC8 proteins form the
channel pore. Our work suggests that LRRC8D-containing VRACs
are crucial for cell volume regulation by an important organic osmo-
lyte and may influence cisplatin/carboplatin responsiveness of tumors.
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Introduction
The platinum-containing drugs cisplatin, carboplatin, and oxali-
platin are among the most successful drugs used for treating cancer
(Kelland, 2007). Pt drugs introduce covalent adducts in DNA which
eventually cause cell death. Tumor cells treated with therapeutic
doses of Pt drugs probably die predominantly by mitotic catastro-
phe/necrosis (Borst et al, 2001; Brown & Attardi, 2005). Attempts to
link Pt drug sensitivity to apoptosis remain prominent (Speirs et al,
2011), however, even though the induction of apoptosis by high
drug concentrations has been shown to be due to a cytoplasmic off-
target effect of Pt drugs (Mandic et al, 2003; Berndtsson et al, 2007;
Fayad et al, 2009).
In cultured cells, the induction of apoptosis by cisplatin and
other drugs such as staurosporine is characterized by an early cell
shrinkage denominated apoptotic volume decrease (AVD) which is
followed by other apoptotic hallmarks like the activation of
caspases and DNA fragmentation. AVD and the induction of apop-
tosis could be inhibited by blockers of the ubiquitously expressed
volume-regulated anion channel VRAC (also known as VSOR or
VSOAC) (Maeno et al, 2000; Ise et al, 2005; Okada et al, 2006; Lang
& Hoffmann, 2012). Being closed under resting conditions, VRAC
opens upon cell swelling and releases chloride and organic osmo-
lytes in the course of regulatory volume decrease (RVD). The effect
of VRAC blockers on drug-induced apoptosis was attributed to a
loss of VRAC-dependent AVD (Maeno et al, 2000). However, the
blockers used to substantiate a role of VRAC in apoptosis are all
non-specific, and the notion that AVD facilitates apoptosis is
controversial (Orlov et al, 2013). VRAC has been characterized
biophysically and physiologically for decades, but the failure to
identify the underlying proteins (Okada, 1997; Pedersen et al, 2015)
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precluded conclusive genetic and biochemical studies. Only
recently, LRRC8 heteromers were identified as essential VRAC
components. LRRC8A is an obligatory VRAC subunit (Qiu et al,
2014; Voss et al, 2014), but it needs at least one other LRRC8
homolog (LRRC8B, LRRC8C, LRRC8D, or LRRC8E) to mediate
volume-activated anion currents (ICl,vol) or to release organic
osmolytes like taurine (Voss et al, 2014). A weak homology to
pannexins suggests that LRRC8 proteins may assemble to hexameric
channels (Abascal & Zardoya, 2012). The formation of different
LRRC8 heteromers indicates that there are several different VRACs
that may vary in properties and tissue distribution. For instance, the
subunit composition of LRRC8 heteromers might specify the
channel’s preference for chloride over taurine or vice versa. Such
a scenario would support the contentious notion (Lambert &
Hoffmann, 1994; Stutzin et al, 1999; Shennan, 2008) that VRAC is
molecularly distinct from a postulated volume-stimulated organic
osmolyte/ anion channel VSOAC (Jackson & Strange, 1993).
However, the impact of specific LRRC8 subunits on VRAC’s
selectivity has not yet been investigated.
An unbiased genomic screen now revealed that the loss of either
of two VRAC subunits, LRRC8A or LRRC8D, increased resistance
against carboplatin and cisplatin. This finding can be largely
explained by an unsuspected role of VRAC in drug transport. This
transport required the obligatory channel subunit LRRC8A and also
depended on LRRC8D, a subunit that strongly increased VRAC’s
permeability to cisplatin/carboplatin. Exposure to staurosporine
revealed an additional, drug uptake-independent, but possibly AVD-
related effect of LRRC8A on drug-induced apoptosis. Moreover,
LRRC8D increased VRAC’s permeability to taurine, and cells lacking
this subunit showed reduced cell volume regulation. Our work
uncovers a novel role of VRAC in cisplatin and carboplatin uptake
and resistance, identifies LRRC8A/LRRC8D-containing VRACs as
physiologically important organic osmolyte channels, and reveals
differences in substrate selectivity and pharmacology between
differently composed VRACs.
Results
A genomewide screen identifies LRRC8A and LRRC8D as
mediators of carboplatin and cisplatin resistance
To identify genes affecting platinum drug sensitivity, we performed
genomewide loss-of-function screens of haploid KBM7 cells that
were subjected to insertional mutagenesis using a gene-trap virus
(Carette et al, 2009) (Fig 1A). Cells resisting exposure to 7 lM
carboplatin for three weeks showed a significant enrichment of
insertions in the LRRC8D and LRRC8A genes (Fig 1B and
Appendix Table S1). Most sense insertions were localized in introns
upstream of the ORF-containing exon 3 (Fig 1C). These positions
are consistent with gene-inactivating mutations. Two LRRC8D-
deficient KBM7 clones, which display reduced blasticidin S uptake
(Lee et al, 2014) and which lack the LRRC8D protein (Fig EV1),
were indeed more resistant to both carboplatin and cisplatin,
but not to the larger compound oxaliplatin (Fig 1D and
Appendix Table S2). Likewise, KBM7-derived haploid HAP1 cells
(Carette et al, 2011) were resistant to carboplatin and cisplatin, but
not to oxaliplatin, when LRRC8A or LRRC8D was disrupted
(Fig EV2). Hence, two genes, LRRC8A and LRRC8D, affected carbo-
and cisplatin sensitivity at drug concentrations that can be achieved
in patients.
Low LRRC8D expression correlates with reduced survival of
Pt drug-treated ovarian cancer patients
To determine whether LRRC8A or LRRC8D expression might affect
chemotherapy in patients, we examined The Cancer Genome Atlas
(TCGA) data collection of ovarian cancer patients who were treated
with platinum drugs. We analyzed the survival of patients with a
low tumor expression of LRRC8A or LRRC8D versus the remaining
patients. We used the lower tertile of the distribution of LRRC8A
and LRRC8D expressions as cutoff. Whereas low LRRC8A expres-
sion had no influence on survival (Fig 2A), patients with a low
LRRC8D gene expression in their ovarian cancers displayed a signif-
icantly reduced survival (Fig 2B). Most patients had also received
taxane, but disruption of LRRC8A or LRRC8D did not provide resis-
tance against docetaxel (Appendix Fig S1). To corroborate these
results, we investigated the data derived from ovarian cancer
patients that were recently published by Patch et al (2015).
Although the available data are derived from fewer patients, also in
this analysis a low expression of LRRC8D, but not LRRC8A, corre-
lated with a modest, but significant decrease in survival (Fig 2C
and D). Thus, LRRC8D might also affect platinum drug responses in
cancer patients.
Pt drug resistance is not strictly correlated with lack of VRAC
currents or volume regulation
LRRC8A and LRRC8D are subunits of the volume-regulated anion
channel VRAC. The finding that the loss of LRRC8D conferred drug
resistance was surprising because this subunit, unlike LRRC8A, is
dispensable for VRAC Cl currents (ICl,vol) in HCT116 cells (Voss
et al, 2014), a finding we now confirmed for haploid HAP1 and
KBM7 cells (Fig 3A and B, Appendix Fig S2). Hence, Pt drug resis-
tance is not correlated with a loss of VRAC Cl channel activity.
In view of the postulated role of VRAC activation in cisplatin-
induced cell shrinkage and subsequent apoptotic cell death (Maeno
et al, 2000; Okada et al, 2006; Lang & Hoffmann, 2012), we
explored the role of LRRC8A and LRRC8D in regulatory volume
decrease (RVD) that can be determined more reliably than
AVD. Like ICl,vol (Voss et al, 2014), RVD depended on LRRC8
heteromers because it was similarly impaired in LRRC8A/ and
LRRC8(B,C,D,E)/ cells that lack LRRC8 isoforms B through E
(Fig 3C). In LRRC8D/ cells, notwithstanding unchanged ICl,vol
amplitudes (Fig 3A and B; Voss et al, 2014), RVD was significantly
reduced but not abolished (Fig 3C). Hence, it seems unlikely that
LRRC8D disruption protects cells against cisplatin toxicity by
impairing VRAC- and AVD-dependent apoptosis.
LRRC8-dependent induction of apoptosis by cisplatin
and staurosporine
We next measured drug-induced activation of caspase-3 to test
whether the induction of apoptosis by staurosporine or high
concentrations of cisplatin depends on LRRC8 subunits. Cisplatin-
induced caspase activation was indeed suppressed in LRRC8A/,
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LRRC8D/, and LRRC8/ cells that lack all LRRC8 subunits
(Fig 4A). To explore whether activation of VRAC by hypotonic
swelling facilitated cisplatin-induced apoptosis, we exposed cells
during 1 h to 200 lM cisplatin in hypotonic medium (25%)
and measured caspase activity after 1 to 3 days. This procedure
drastically increased caspase activation in WT cells (Fig 4B).
A
B
D
C
Figure 1. Loss-of-function screen using haploid KBM7 cells identifies LRCC8A and LRRC8D as determinants of carboplatin resistance.
A Outline of the loss-of-function screen.
B Genes enriched for gene-trap insertions in a carboplatin-selected cell population compared to unselected control cells. Circles represent genes and their size
corresponds to the number of independent insertions identified in the carboplatin-selected population. Genes are ranked on the x-axis based on chromosomal position.
C Location of gene-trap insertion sites (red arrowheads). White boxes indicate the 50- and 30-untranslated regions, and the black boxes show the coding sequence in
exons 3 and 4 (LRRC8A) and exon 3 (LRRC8D).
D Loss of LRRC8D causes resistance to carboplatin and cisplatin, but not to oxaliplatin. Survival of parental, vector-transduced, or LRRC8D-deficient GT1 and GT2 KBM7
cells exposed for 96 h to increasing concentrations of cisplatin, carboplatin, and oxaliplatin. The corresponding IC50 values and 95% confidence interval (CI) are given
in Appendix Table S2. Data are presented as mean  SEM.
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Swelling-enhanced caspase induction by cisplatin depended on
VRAC as it was abolished in LRRC8A/ and LRRC8/ cells. It was
strongly reduced, but not abolished, in LRRC8D/ cells (Fig 4B).
By contrast, staurosporine-induced caspase activation was not
enhanced by hypotonic swelling and was suppressed in LRRC8A/,
but not in LRRC8D/ cells (where it was rather increased for
unknown reasons) (Fig 4C). Since both ICl,vol and caspase induc-
tion by staurosporine depend on LRRC8A but not LRRC8D, these
results are compatible with the hypothesis that VRAC activation-
dependent AVD facilitates the progression of apoptosis (Maeno
et al, 2000; Shimizu et al, 2004). VRAC activation by pro-apoptotic
stimuli was monitored by the quenching of YFP fluorescence by
externally added iodide (Voss et al, 2014). Iodide permeates VRAC
efficiently and hence VRAC opening increases YFP quenching rates.
The slow emergence of an LRRC8A-dependent quenching compo-
nent upon incubation with 200 lM cisplatin (Fig 5A–C) or 4 lM
staurosporine indicated that both drugs slowly activated VRAC
(Fig 5E and F). Drug-induced VRAC activation was small compared
to that elicited by acute hypotonic cell swelling (Fig 5D). A direct
comparison of quenching slopes, however, underestimates the
difference in activation because quenching rates after acute expo-
sure to hypotonicity (but not with drug preincubation) also reflect
the time course of cell swelling and ensuing VRAC opening
(Appendix Fig S2A and E).
VRAC mediates cisplatin uptake which depends on LRRC8
subunit composition
The observation that cisplatin activated caspase-3 in WT cells more
efficiently when applied in hypotonic medium suggested that
cisplatin might enter cells through VRACs. Indeed, VRACs not only
conduct halide ions, but also organic compounds like taurine,
A B
C D
Figure 2. Low expression of LRRC8D but not LRRC8A correlates with shorter survival of high grade serous ovarian cancer patients treated with platinum-
based drugs.
A–D Differential survival based on LRRC8A (A, C) or LRRC8D (B, D) gene expression as extracted from the TCGA database (http://cancergenome.nih.gov/) (A, B) or using the
data from Patch et al (2015) (C, D). As cutoff the lower tertile of LRRC8A or LRRC8D gene expression was used. P-values were determined using the log-rank test.
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glutamate, and blasticidin (Jackson & Strange, 1993; Hyzinski-
Garcı´a et al, 2014; Lee et al, 2014; Qiu et al, 2014; Voss et al, 2014).
Importantly, early studies on a variety of cultured cell lines have led
to the conclusion that cisplatin/carboplatin uptake involves two
components: About half the drug enters cells by passive diffusion
through the plasma membrane and the other half via a protein
component, possibly a channel (reviewed by Gately & Howell,
1993). We therefore measured the cellular accumulation of Pt-based
drugs by determining Pt concentrations in extracts of cells of various
LRRC8 genotypes.
Under isotonic conditions, drug uptake performed at therapeutic
carboplatin concentrations (7 lM) by drug-resistant LRRC8D/
KBM7 cell clones was indeed reduced ~twofold compared to control
(Fig 6A). The effect of VRAC subunits in Pt drug uptake was
explored in detail for cisplatin in HEK and HCT116 cells of different
LRRC8 genotypes. The underlying uptake processes did not saturate
with cisplatin concentrations up to 400 lM in both WT and
LRRC8A/ cells (Fig EV3), allowing us to use concentrations
exceeding therapeutic levels to increase the sensitivity of the assay.
When uptake was performed over several hours under isotonic
conditions, cisplatin accumulation was reduced by roughly 70 and
50% upon disruption of LRRC8A or LRRC8D, respectively (Fig 6C
(HEK cells), Fig EV4A (HCT cells)). This subunit dependence resem-
bled that observed with cellular carboplatin and cisplatin resistance
(Figs 1 and EV2). The LRRC8-dependent uptake component
increased with variable time course over the first few hours (Figs 6C
and E, EV4A and EV5). When uptake was studied in isotonic saline
for 1 h or less, no significant influence of either LRRC8A or LRRC8D
was detected (Fig 6D and E, highlighted by dashed line, and
Fig EV4B). Isotonic cisplatin uptake thus appears to be associated
with a rather slow activation of VRAC in these cells, which we
(Fig 5) and others (Shimizu et al, 2004; Poulsen et al, 2010; Min
et al, 2011; Cai et al, 2015) have observed in response to pro-apop-
totic drugs.
Hypotonic cell swelling activates VRAC anion currents within a
few minutes (Nilius et al, 1997; Voss et al, 2014) (Appendix Fig S2A
and E). A 25% decrease in osmolarity during 15- or 60-min uptake
periods indeed increased cisplatin accumulation several-fold
(Figs 6D and F (HEK), and EV4B, Appendix Fig S3 (HCT116)).
Whereas long-term isotonic uptake was almost as strongly reduced
in LRRC8D/ as in LRRC8A/ cells, the hypotonicity-stimulated
cisplatin uptake component was abolished in LRRC8A/ cells, but
reduced by only up to 50% in LRRC8D/ cells (Figs 6D (HEK) and
EV4B (HCT116)). Like ICl,vol (Voss et al, 2014), swelling-induced
cisplatin uptake was normal in LRRC8C/ cells (Fig 6D), abolished
in LRRC8(B,C,D,E)/ cells (which express only LRRC8A)
(Appendix Fig S3), and was suppressed by the VRAC inhibitor
carbenoxolone (Ye et al, 2009; Voss et al, 2014) (Fig 6B). These find-
ings indicated that VRACs (LRRC8 heteromers) transport Pt-based
drugs and suggest a special role of LRRC8D-containing channels.
VRACs might be hetero-hexamers of LRRC8 proteins (Abascal &
Zardoya, 2012; Voss et al, 2014), and HEK and HCT116 cells
express all five LRRC8 genes (Fig EV1). This suggests a highly
heterogeneous VRAC population. We reduced this complexity by
studying LRRC8(B,D,E)/, LRRC8(B,C,E)/, and LRRC8(B,C,D)/
cells that can only express LRRC8A/C, LRRC8A/D, and LRRC8A/E
heteromeric channels, respectively. Long-term, isotonic cisplatin
accumulation by A/D-expressing cells was much larger than by
LRRC8A/ cells (Figs 6E and EV5), whereas cells expressing A/C
heteromers (Fig 6E) or A/E heteromers (Fig EV5) took up as
little cisplatin as LRRC8A/ cells. Hypotonicity enhanced
short-term cisplatin uptake to almost the same extent in WT- and
LRRC8A/D-expressing cells (Fig 6F). LRRC8A/C heteromers
appeared to enable cisplatin uptake upon cell swelling, but to a
A C
B
Figure 3. Disruption of LRRC8A, but not of LRRC8D, abolishes ICl,vol and blocks volume regulation.
A, B VRAC currents (ICl,vol) of the HAP1 (A) and KBM7 (B) haploid cell lines. Left panels, example current traces of ICl,vol fully activated by hypotonic cell swelling measured
with the voltage-clamp protocol shown in (A). Dashed lines indicate zero current. Right panels, averaged current/voltage relationships of maximally activated
ICl,vol. Consistent with VRAC currents, they needed hypotonic swelling for activation, displayed an I
 > Cl permeability sequence, and were blocked by DCPIB
(Appendix Fig S2A–H). The difference in current inactivation between HAP1 and KBM7 cells can be explained by the fact that KBM7 cells hardly express LRRC8E
(Fig EV1) which accelerates VRAC inactivation (Voss et al, 2014). At potentials > +100 mV, also KBM7 currents inactivated (Appendix Fig S2I). Data are presented as
mean  SEM; n = 5–10.
C Dependence of regulatory volume decrease (RVD) of HEK cells on LRRC8 genes. Cells were exposed to hypotonic medium starting at t = 0, and intracellular calcein
fluorescence was followed over ~1 h as semiquantitative measure of cell volume. Data are presented as mean values  SEM from sixteen wells.
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much smaller degree than LRRC8A/D heteromers or WT VRAC
(Fig 6F). Importantly, amplitudes of swelling-activated Cl currents
of A/C-expressing cells were similar to WT ICl,vol, but were much
smaller with A/D heteromers (Fig 6G)—a finding agreeing with
heterologous expression studies (Voss et al, 2014). Hence, LRRC8D-
containing heteromers display a considerably higher cisplatin/Cl
transport ratio than other LRRC8 heteromers (Fig 6H).
VRAC Cl currents are inhibited by cisplatin–DMSO complexes in
a LRRC8D-dependent manner
In a high-throughput drug screen for VRAC transport inhibitors, in
which compounds were routinely dissolved in DMSO, we identified
cisplatin as putative VRAC blocker (data not shown). However,
suppression of ICl,vol required DMSO, with which cisplatin forms
adducts like Pt(NH3)2(Cl)(DMSO) (Fischer et al, 2008). Cisplatin–
DMSO complexes inhibited native ICl,vol of HEK cells in a dose-
dependent manner (Fig 7A), but had no effect on currents of
LRRC8D/ cells (Fig 7B). Hence, differently composed LRRC8
channels can also differ in their pharmacology, and cisplatin-
conducting VRACs might be specifically targeted without abolishing
ICl,vol and cell volume regulation.
Swelling-induced release of the cellular osmolyte taurine
depends on LRRC8D
Whereas LRRC8D/ cells displayed unchanged swelling-activated
Cl currents (ICl,vol) (Figs 3A and B, and 6G; Voss et al, 2014), their
RVD was markedly decreased (Fig 3C). We therefore hypothesized
that LRRC8D is not only important for the transport of cis- and
carboplatin, but also of organic osmolytes that do not contribute to
electric currents. Indeed, LRRC8D disruption drastically reduced
swelling-induced efflux of the important cellular osmolyte taurine
(Fig 8A), but had less of an effect than disruption of LRRC8A that
apparently totally abolishes swelling-induced taurine efflux (Voss
et al, 2014). Transient transfection of LRRC8D, which is difficult
to express heterologously (Voss et al, 2014), partially rescued
taurine efflux (Fig 8B). Taurine efflux from A/D-expressing cells
resembled WT fluxes (Fig 8C), whereas LRRC8C or LRRC8E failed to
support significant taurine flux as revealed by experiments with
LRRC8(B,D,E)/ and LRRC8(B,C,D)/ cells in which only LRRC8A
and LRRC8C or LRRC8E, respectively, remain (Fig 8D and E).
The reduced RVD of LRRC8D/ cells (Fig 3C) thus exposes the
importance of taurine and possibly other organic osmolytes in
cell volume regulation.
Like VRAC-dependent I influx (Fig 5A–C), also VRAC-mediated
taurine efflux was stimulated by preincubation with cisplatin
(Fig 8F). In congruence with the weaker stimulation of iodide flux
by cisplatin than by hypotonicity (Fig 3), cisplatin preincubation
stimulated taurine efflux much less than hypotonic swelling. The
cisplatin-induced efflux component increased with the time of
A
B
C
Figure 4. LRRC8 subunit- and osmolarity-dependent caspase induction
in HCT116 cells.
A, B Cisplatin-induced caspase activity in the continuous presence of 200 lM
cisplatin under isotonic conditions (A), or after 1 h exposure to 200 lM
cisplatin under iso- and hypotonic conditions (B), was followed over time
in WT, LRRC8A/, LRRC8D/, and LRRC8/ HCT116 cells. Results from
LRRC8A/ and LRRC8D/ were obtained with two different clonal cell
lines each and averaged.
C Caspase activation after 1-h exposure to 4 lM staurosporine under iso-
or hypotonic conditions of WT, LRRC8A/, LRRC8D/, and LRRC8/
HCT116 cells.
Data information: Data are presented as mean  SEM, n = 3–6. *P < 0.05;
**P < 0.01; and ***P < 0.001. Similar results were obtained in three
independent experiments. Fold change in (A) refers to t = 0. Control
experiments indicated that hypotonicity per se had no effect (Appendix Fig S4).
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A B
C D
E F
Figure 5. Activation of LRRC8 channels by pro-apoptotic stimuli.
A–C Cisplatin-induced iodide influx into WT (black ■), but not LRRC8A/ (green ▼) HEK cells indicates VRAC halide current activation during apoptosis. Cells
expressing an iodide-sensitive YFP variant were exposed to 200 lM cisplatin for periods of 0.5 h (A), 4.5 h (B), or 8.5 h (C) before adding extracellular I (50 mM
final). The difference in slopes of YFP fluorescence quenching between control and cisplatin-treated cells semiquantitatively reflects VRAC current activation. Note
that increased YFP quenching with cisplatin preincubation is not due to large non-specific leaks resulting from cell morbidity. Such leaks should lead to a fast
component of YFP quenching in WT, but not LRRC8A/ cells after the pipetting artifact that immediately follows addition of iodide (indicated by arrows).
D Swelling-induced iodide influx into WT (black ■) and LRRC8A/ (green ▼) HEK cells for comparison. Iodide (50 mM final) was added in isotonic or hypotonic
(230 mOsm final) solution at the time indicated by arrow.
E, F Time course of VRAC activation by 200 lM cisplatin (E) or 4 lM staurosporine (F) determined as in (A–C). Averaged maximal slopes of YFP quenching from eight
wells (E) or 16 wells (F) each were evaluated to estimate iodide influx rates. WT (black ■) and LRRC8A/ (green ▼). Data are presented as mean  SEM.
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preincubation and was abolished in LRRC8A/ cells. Taurine efflux
did not occur through cell morbidity-related unspecific leaks since it
could be blocked by carbenoxolone (Fig. 8F). WT VRACs seemed to
transport taurine at low rates also without stimulation by cisplatin
as indicated by the reduced efflux from cells lacking LRRC8A.
However, at these low transport rates, we cannot exclude that
slight and variable osmotic imbalances marginally opened VRAC
as steady-state efflux differed between experiments (compare
Fig 8A–E).
Discussion
Our work indicates that heteromeric LRRC8 channels (VRACs)
can transport cisplatin and carboplatin, widely used anti-cancer
drugs, and that the substrate selectivity and pharmacology of
VRAC depend on its subunit composition. LRRC8D plays impor-
tant pharmacological and physiological roles in supporting the
transport of anti-cancer drugs and of the organic osmolyte
taurine. LRRC8 channels also facilitated drug-induced apoptosis
independent of drug transport, revealing a dual role of VRAC in
cisplatin toxicity.
LRRC8 channels in drug-induced apoptosis
Several groups have reported that inhibition of bona fide VRAC
(VSOR, VSOAC) by various non-specific compounds impaired the
induction of apoptosis by drugs such as cisplatin and staurosporine
(Maeno et al, 2000; Ise et al, 2005; Okada et al, 2006; d’Anglemont
de Tassigny et al, 2008; Poulsen et al, 2010). These findings were
attributed to an impairment of VRAC-dependent apoptotic volume
decrease (AVD) which is thought to be crucial for the progression of
apoptosis (Maeno et al, 2000) (for recent reviews, see Hoffmann &
Lambert, 2014; Lang & Hoffmann, 2012). Indeed, cisplatin and other
drugs lead to a slow activation of currents with typical characteris-
tics of ICl,vol, and the resulting AVD could be reduced by
non-specific VRAC inhibitors (Shimizu et al, 2004; Poulsen et al,
2010; Min et al, 2011; Cai et al, 2015). Moreover, several cancer
drug-resistant cell lines display less ICl,vol, AVD, RVD, and swelling-
activated taurine efflux than their parent cells (Lee et al, 2007;
Poulsen et al, 2010; Min et al, 2011; Sørensen et al, 2014). In KCP-4
cells, both cisplatin sensitivity and ICl,vol were partially restored in
parallel by non-specific changes in gene expression using a histone
deacetylase inhibitor (Lee et al, 2007). Since some of those cell lines
are resistant to various anti-cancer drugs that probably enter cells
through different pathways, these reports suggested that VRAC
downregulation entailed drug resistance through an AVD-dependent
mechanism.
Because LRRC8A was required for both ICl,vol and pro-apoptotic
drug-induced iodide influx or taurine efflux, our data now strongly
suggest that LRRC8 channels are involved in both RVD and AVD.
Since disruption of the obligatory VRAC subunit LRRC8A also
reduced the activation of caspase-3 by two pro-apoptotic stimuli,
staurosporine and cisplatin, our results are compatible with the
notion that apoptosis is facilitated by an LRRC8A-dependent volume
decrease. The requirement for LRRC8D in cisplatin-induced, but not
in staurosporine-induced caspase activation, can be explained by
different mechanisms of cellular uptake. Staurosporine, a large
hydrophobic compound that may cross membranes by passive diffu-
sion, apparently does not enter cells through VRAC since it activated
caspases regardless of whether it was applied in iso- or hypotonic
medium. By contrast, cisplatin permeates through VRACs, in partic-
ular those containing LRRC8D subunits. This uptake mechanism
imposes an additional LRRC8D dependence on caspase induction by
cisplatin.
Cisplatin and carboplatin uptake through VRAC
Like ICl,vol and taurine efflux (Voss et al, 2014), cellular cisplatin
uptake was strongly stimulated by hypotonic swelling, as reported
previously (Smith & Brock, 1989). This uptake component was
abolished in LRRC8A/ and LRRC8(B,C,D,E)/ cells which do
not express functional VRACs and was inhibited by the VRAC
inhibitor carbenoxolone. Furthermore, caspase activation by
cisplatin showed a similar dependence on LRRC8 isoforms and
medium tonicity as cisplatin uptake as is expected for an intra-
cellular effect of cisplatin. Our results, which were obtained with
up to four different cell lines and several independent LRRC8
knockout clones that excluded off-target effects, constitute over-
whelming evidence that LRRC8 channels directly transport
cisplatin and carboplatin.
About 50 to 70% of long-term isotonic cisplatin uptake was
dependent on LRRC8D and LRRC8A, respectively. The uptake
component remaining in LRRC8A/ and LRRC8(B,C,D,E)/ cells
probably represents passive diffusion across the plasma membrane
(Gately & Howell, 1993). The dependence on LRRC8D was surpris-
ing since this isoform is dispensable for ICl,vol (Voss et al, 2014).
Drug uptake through VRAC was also unexpected since this channel
is thought to be closed under isotonic conditions (Nilius et al,
1997), which prevents a continuous loss of cellular constituents like
amino acids. However, LRRC8-dependent isotonic uptake of
cisplatin in HEK cells developed with a time course that was
▸Figure 6. LRRC8 subunit- and osmolarity-dependent carboplatin/cisplatin transport.A Carboplatin uptake into control KBM7 cells and two LRRC8D-deficient clones (n = 6).
B Hypotonicity-stimulated cisplatin uptake in HEK WT cells was selectively blocked by 100 lM carbenoxolone (CBX), a non-specific blocker of VRAC (n = 3).
C, D Cisplatin uptake into HEK cells of indicated genotypes using 40 lM cisplatin under long-term isotonic (C) or 200 lM cisplatin in short-term hypo- and isotonic (D)
conditions as function of time (n = 3). Similar results were obtained in HCT116 cells (Fig EV4).
E, F Cisplatin uptake (200 lM) into HEK cells of indicated genotypes. LRRC8(B,C,E)/ and LRRC8(B,D,E)/ cells express only LRRC8A and LRRC8D, and LRRC8A and
LRRC8C, respectively (n = 3 for WT, 6 for LRRC8D/, 9 for LRRC8A/ in E; n = 3 in F).
G Mean current densities of maximally activated ICl,vol at 80 mV. The number of cells is indicated for each column.
H Ratio of LRRC8-dependent swelling-activated cisplatin uptake (60 min) to mean ICl,vol (as in G) as function of genotype.
Data information: Data are presented as mean  SEM. *P < 0.05; **P < 0.01; and ***P < 0.001 (for (C, E) compared to LRRC8A/ cells). Dotted lines in (D) and (F)
highlight that there is no significant difference in isotonic 60-min uptake between the genotypes.
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consistent with a slow drug-induced activation of VRAC. Previously,
the activation of bona fide VRAC channels or AVD by 5–15 lM
cisplatin has been observed after time lags that ranged from
~20 min (Min et al, 2011; Cai et al, 2015) to ~4 h (Poulsen et al,
2010). The time course of drug-induced activation of LRRC8A-
dependent iodide and taurine fluxes observed here is consistent
with those previous findings. It appears that only a small fraction of
VRAC is activated by pro-apoptotic stimuli because the observed
iodide, taurine, and cisplatin transport rates were roughly an order
of magnitude lower than those obtained with strong hypotonic stim-
uli. This fits the low VRAC current amplitudes observed by others
(Shimizu et al, 2004) upon exposure of cells to pro-apoptotic drugs.
Our data suggest that cisplatin, after having entered cells through
passive diffusion across the plasma membrane, opens VRAC as an
additional pathway for its uptake. This feedforward mechanism
results in additional cisplatin-induced cisplatin uptake.
Dual role of LRRC8 in drug resistance: drug uptake and AVD-
related apoptosis
Many biochemical alterations result in resistance to Pt-based anti-
cancer drugs of cultured cells, but it has remained unclear which
proteins are involved in medically relevant Pt drug transport (Borst
et al, 2008; Hall et al, 2008; Burger et al, 2011; Ivy & Kaplan, 2013).
We now identified VRAC as a major uptake mechanism for cis- and
carboplatin. As VRACs mediated about half of isotonic cisplatin
uptake, downregulation of LRRC8 subunits could have significant
impact on tumor drug resistance. While requiring confirmation by
prospective studies, this notion is supported by our analysis of two
independent data sets from ovarian cancer patients: LRRC8D down-
regulation correlated with poor survival of Pt drug-treated patients.
No correlation was seen with reduced LRRC8A expression, possibly
because LRRC8A-dependent volume regulation is a viability factor
for cells.
In addition to its role in cisplatin/carboplatin uptake, VRAC
facilitated apoptosis through an independent, possibly AVD-related
mechanism. An impairment of apoptosis may further contribute to
drug resistance (Kelly & Strasser, 2011; Speirs et al, 2011),
although tumor cells treated with therapeutic doses of Pt drugs
probably die predominantly by other mechanisms (Borst et al,
2001; Brown & Wilson, 2003; Brown & Attardi, 2005). Acute
induction of apoptosis in HCT116 cells, as analyzed in Fig 4, is
thought to require cisplatin concentrations that are ~10-fold higher
than therapeutic ones (Berndtsson et al, 2007). Such an induction
is independent of nuclear DNA damage (Mandic et al, 2003) and
depends on the production of reactive oxygen species (ROS)
(Berndtsson et al, 2007) which can activate VRACs (Shimizu et al,
2004; Varela et al, 2004). Therefore, the relevance of VRAC-
facilitated apoptosis at therapeutic doses remains to be determined
in tumors of patients.
LRRC8D increases VRAC’s permeability for cisplatin/carboplatin
and taurine
Whereas the obligatory LRRC8A subunit is required for the surface
expression of VRAC, no specific roles could be assigned so far to the
other subunits, except for an influence on the kinetics of inactiva-
tion at non-physiological voltages (Voss et al, 2014). We have now
discovered a role of LRRC8D in taurine and cisplatin/carboplatin
transport that is biologically and medically important. Although
LRRC8D disruption did not decrease swelling-activated Cl currents
(ICl,vol) (Fig 3A and B; Voss et al, 2014), it reduced both isotonic
and swelling-activated cisplatin uptake and blunted the ensuing acti-
vation of caspases. Comparison of swelling-induced cisplatin and
Cl transport (ICl,vol) revealed that the incorporation of LRRC8D
substantially increased VRAC’s cisplatin/Cl transport ratio, as most
strikingly demonstrated by the > 10-fold different transport ratio
between LRRC8A/D and LRRC8A/C channels. The substantial
swelling-activated cisplatin transport remaining in LRRC8D/ cells
(Figs 6D and EV4B) indicates that the cisplatin permeability of
VRAC is not absolutely dependent on LRRC8D. LRRC8A/C and
LRRC8A/E heteromers transported cisplatin very poorly under
isotonic conditions (Figs 6E and EV5), but significant, albeit small,
transport through A/C channels could be elicited by cell swelling
(Fig 6F). Hence, even A/C channels may, in principle, transport
A
B
Figure 7. Cisplatin–DMSO inhibition of ICl,vol depends on the LRRC8D
subunit.
A Upper panel, example current traces (as in Fig 3A) of fully activated ICl,vol in
HEK cells exposed to hypotonic solution containing vehicle (0.3% DMSO) or
200 lM cisplatin in 0.3% DMSO. Dashed lines indicate zero current. Lower
panel, ICl,vol current densities (at 100 mV and 100 mV) of WT HEK cells
treated with different cisplatin concentrations.
B No effect of 200 lM cisplatin/DMSO on ICl,vol in LRRC8D
/ HEK cells.
Data information: Data are presented as mean  SEM; the number of
experiments is given for each bar; *P < 0.05; **P < 0.01.
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Figure 8. LRRC8A/LRRC8D-containing channels transport the cellular osmolyte taurine.
A, B Swelling-induced efflux of 3[H]-taurine from WT and LRRC8D/ HEK cells (A, B) and partial rescue by transient transfection of LRRC8D (B). Rescue is incomplete
due to low transfection/expression efficiency of LRRC8D (Voss et al, 2014).
C–E Swelling-induced efflux of 3[H]-taurine from LRRC8(B,C,E)/ (C), LRRC8(B,D,E)/ (D), or LRRC8(B,C,D)/ (E) HEK cells compared to WT cells.
F Cisplatin-induced taurine efflux (over 30 min) from WT and LRRC8A/ HEK cells after preincubation with 200 lM cisplatin for 4 or 12 h, or without cisplatin (0 h).
Carbenoxolone (CBX; 100 lM) blocks taurine efflux from WT cells treated for 12 h with cisplatin, excluding taurine flux through unspecific leaks.
Data information: Data are presented as mean  SEM. Dashed lines in (A–E) represent isotonic efflux from the same individual experiments. Red arrows, change to
hypotonic solution. Each panel shows the average of two independent experiments (n = 4 for each experiments, i.e., n = 8 in total).
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cisplatin. Possible roles of other subunits and subunit combinations
remain to be explored.
A mere loss of LRRC8D-containing, cisplatin-preferring channels
should have quantitatively similar effects on isotonic and hypotonic
uptake. However, whereas under long-term isotonic conditions,
LRRC8D disruption reduced the LRRC8-dependent component (as
defined by the difference between WT and LRRC8A/ cells) by
~70%, the hypotonicity-stimulated cisplatin uptake component was
diminished by only ~50% or less in LRRC8D/ cells. This disparity
suggests a differential activation of LRRC8D-containing heteromers
by pro-apoptotic drugs or cell swelling.
LRRC8D also plays a prominent physiological role. It crucially
determines VRAC’s taurine permeability, but mirroring its role in
cisplatin transport, it is not absolutely required for taurine trans-
port. Taurine, the cellular concentrations of which range from 5 to
50 mM, is an important cellular osmolyte and has several addi-
tional biological roles (Lambert et al, 2015). LRRC8D/ cells can
now be used to estimate the contribution of organic osmolytes to
cell volume regulation. Our RVD experiments suggest that this
contribution is substantial. The simultaneous presence in the
plasma membrane of VRACs incorporating or lacking LRRC8D
subunits probably explains previous observations which suggested
that the volume-regulated anion channel VRAC is molecularly
distinct from a volume-sensitive organic osmolyte and anion
channel VSOAC (Lambert & Hoffmann, 1994; Stutzin et al, 1999;
Shennan, 2008).
Implications for the pore of VRACs
The dependence of the substrate selectivity on subunit composition
is compelling evidence that LRRC8 heteromers form the VRAC pore.
The structural basis of VRAC selectivity is currently unknown.
Remarkably, VRACs are thought to display a substantial
anion > cation selectivity for inorganic ions (Nilius et al, 1997),
while also transporting rather large organic substrates. The radius of
the VRAC pore has been estimated to be 0.6–0.7 nm (Droogmans
et al, 1999; Ternovsky et al, 2004). This value is compatible with
the release of organic osmolytes like taurine and amino acids and
also with the uptake of cisplatin and carboplatin (maximal radius of
~0.15 and ~0.28 nm, respectively). On the other hand, this simple
consideration does not explain the observation that oxaliplatin
(r ~ 0.45 nm) did not permeate, whereas blasticidin S (r ~ 0.7 nm)
apparently does (Lee et al, 2014).
The conundrum of a highly halide-selective pore that also
conducts much larger and differently charged organic substrates
rests on the assumption that there is just one VRAC, and not a
whole spectrum of differently composed LRRC8 heteromers, that is,
different VRACs. Given the wide tissue distribution of most LRRC8
isoforms, it is likely that various VRACs with diverse properties are
co-expressed in the same cell. Our work is compatible with the
possibility that some subunit combinations form channels that only
conduct organic substrates, whereas others only conduct small
anions. However, since, for example, LRRC8(B,C,E)/ cells trans-
port both organic molecules and Cl, this hypothesis demands that
LRRC8A and LRRC8D can assemble with different stoichiometries
and thereby yield channels with different substrate selectivities. This
proposition, which could apply for other subunit combinations as
well, is difficult to test.
Our work revealed that the specific subunit composition of
VRACs determines their substrate specificity, regulation, and phar-
macology. LRRC8A/LRRC8D-containing VRACs, which are amen-
able to specific pharmacological modulation, are important for cell
volume regulation by organic osmolytes. They may also play an
important dual role in tumor drug sensitivity by mediating cisplatin/
carboplatin uptake and possibly by modulating the progression of
apoptosis.
Materials and Methods
Loss-of-function screens
A haploid-genetic screen for carboplatin resistance was performed
as described (Carette et al, 2011). 108 KBM7 cells were transduced
with a gene-trap retrovirus using spin infection. 108 mutagenized
cells were then exposed to 7 lM carboplatin and distributed over
96-well plates (105 cells/well). Surviving clones were pooled after
21 days and subjected to density centrifugation using lymphocyte
separation medium (Lonza, 30 min at 400 g) to remove cell debris.
Next, 3 × 107 cells were pelleted for genomic DNA isolation
(QiaAmp DNA mini kit, Qiagen). Gene-trap insertion sites were
amplified by inverse PCR. First, genomic DNA was digested using
the restriction enzymes NlaIII and MseI (New England Biolabs)
overnight at 37°C. Fragments were then circularized using T4 DNA
ligase (New England Biolabs) (o/n at RT). Fragments containing the
gene-trap sequence and flanking genomic DNA were amplified by
PCR using primers containing the Illumina adapters P5 and P7 (for
NlaIII-digested DNA: 50-AATGATACGGCGACCACCGAGATCTGAT
GGTTCTCTAGCTTGCC-30 and 50-CAAGCAGAAGACGGCATACGAC
CCAGGTTAAGATCAAGGTC-30; for MseI-digested DNA: 50-AATGAT
ACGGCGACCACCGAGATCTGATGGTTCTCTAGCTTGCC-30 and 50-
CAAGCAGAAGACGGCATACGACGTTCTGTGTTGTCTCTGTCTG-30).
Products were purified (PCR purification kit, Qiagen) and
sequenced on a HiSeq 2000 (Illumina) using a custom sequencing
primer 50-CTAGCTTGCCAAACCTACAGGTGGGGTCTTTCA-30.
Sequence reads were cropped to 36 bp for comparability with
previously performed screens and aligned to the human genome
(hg18) using bowtie (Langmead et al, 2009). Only reads that align
uniquely without mismatches were considered. Additionally, reads
aligning non-uniquely when 1 to 3 mismatches were allowed were
removed, as well as reads falling within 2-bp distance of each other.
As the gene-trap construct is unidirectional, only insertion sites in
the sense orientation of intronic regions, and integrations in sense
or antisense of exonic sequences were considered. To identify genes
enriched in mutations following carboplatin treatment, the number
of insertion sites per gene was compared to an unselected mutage-
nized population (Carette et al, 2011) using a one-sided Fisher exact
test. Correction for multiple testing for P-values was carried out
using Benjamini and Hochberg FDR correction in R.
Cytotoxicity and colony formation assays
LRRC8D-expressing and LRRC8D-deficient KBM7 cells were seeded
in 96-well plates in triplicates (3 × 105 cells per well) and treated
with various concentrations of carboplatin, cisplatin, and oxaliplatin
for 96 h. Relative numbers of viable cells were measured in
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comparison with the untreated control and the solvent control
using the fluorimetrical, resazurin-based Cell Titer Blue assay
(Promega). Measurements were performed according to the
manufacturer’s instructions at 560Ex/590Em nm in a Tecan
counter (Infinite M200). Cell growth was expressed as percentage
of the untreated control.
Regarding HAP1 cells, 10,000 LRRC8A/ HAP1 and 8,000 HAP1
vector control cells were seeded per well into 6-well plates to
account for differences in growth rate. Cells were assayed for colony
formation in the presence of five different concentrations of carbo-
platin, cisplatin, or oxaliplatin. After 7 days, surviving colonies
were formalin-fixed and stained with crystal violet. The optical
absorption was determined at 590 nm after extracting the dye with
10% acetic acid.
LRRC8 knockout cell lines
The generation of stably diploid HCT116 cells and polyploid
HEK293 cells with disruptions in one or several LRRC8 genes using
the CRISPR-Cas9 method has been described previously (Voss et al,
2014). HEK cells lacking LRRC8A-E singly or in various combina-
tions, and HAP1 cells lacking LRRC8A or LRRC8D, were newly
generated using the same procedure. KBM7 clones lacking LRRC8D
were obtained from Hidde Ploegh (Lee et al, 2014). Disruption of
LRRC8 genes was confirmed by genomic sequencing and Western
blotting (Fig EV1).
Antibodies and Western blots
Polyclonal rabbit antibodies against LRRC8A and LRRC8E have been
described previously (Voss et al, 2014). New antibodies were raised
against LRRC8B, LRRC8C and LRRC8D in rabbits using the follow-
ing peptides that were coupled through N-terminally added
cysteines to keyhole limpet hemocyanin: QSLPYPQPGLESPGIESPT,
LRRC8B; EDALFETLPSDVREQMKAD, LRRC8C; LEVKEALNQDVN
VPFANGI, LRRC8D. Sera were purified by affinity to the respective
peptides. Western blots of native HCT116 and HEK cells, together
with cells lacking the respective LRRC8 isoforms, confirmed
the specificity of the antisera, even though some sera (a-LRRC8C,
a-LRRC8D) were made against mouse peptide sequences that dif-
fered by a few amino acids from the human counterparts. Western
blots were done following standard procedures using antibodies
against tubulin or actin as loading controls.
Electrophysiology
VRAC-mediated swelling-activated anion currents ICl,vol were
measured in the whole-cell patch-clamp configuration as described
(Voss et al, 2014). Cells were swollen by exposure to hypotonic solu-
tion (240 mOsm) that differed from the isotonic solution
(320 mOsm: 150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, and 10
HEPES, pH 7.4) by containing 105 instead of 150 mM NaCl. In order
to isolate Cl currents, the pipette solution contained (in mM) the
following: 40 CsCl, 100 Cs-methanesulfonate, 1 MgCl2, 1.9 CaCl2, 5
EGTA, 4 Na2ATP, and 10 HEPES, pH 7.2 (290 mOsm). Whole-cell
currents were monitored by voltage ramps from 100 to +100 mV
and voltage-clamp traces recorded using the protocol shown in
Fig 3A.
Measurement of regulatory volume decrease (RVD)
Cell volume regulation was measured semiquantitatively using the
calcein method (Capo´-Aponte et al, 2005) in a fluorometric imaging
plate reader (FLIPRTM; Molecular Devices) in a 384-well format as
described (Voss et al, 2014). Cell swelling was initiated by decreas-
ing extracellular osmolarity to 94 mOsm, and calcein fluorescence
was followed at k = 515–575 nm for ~65 min.
Drug-induced iodide influx
Iodide influx into HEK cells expressing an iodide-sensitive YFP vari-
ant (Galietta et al, 2001) was carried out using the FLIPRTM as
described (Voss et al, 2014), but using both LRRC8A+/+ and
LRRC8A/ cells. Cells in half of the wells of 384-well plates were
preincubated with 4 lM staurosporine (in 0.4% DMSO; also added
to control wells) or 200 lM cisplatin (without DMSO) for the times
indicated in Fig 7. Iodide uptake (always under isotonic conditions)
was initiated by pipetting 25 ll of a solution containing 70 mM
iodide to the well, resulting in a final iodide concentration of 50 mM.
YFP quenching was followed over time using illumination at
k = 495–505 nm and fluorescence measurement at k = 526–585 nm
using the Fluo3 LED/filter set. Maximal fluorescence quenching rates
were determined as semiquantitative measure of iodide uptake.
Values were averaged from 16 wells for each condition.
Caspase-3 activity determination
Cells covering (~90% confluency) the bottom of 6-cm plates were
incubated at 37°C/5% CO2 in DMEM/FCS containing 4 lM stau-
rosporine, or 0.4% DMSO as vehicle control, or 200 lM cisplatin
(without DMSO). Cells were collected at different times of drug
exposure. To explore the dependence on osmolarity, cells were
incubated with 4 lM staurosporine or 200 lM cisplatin in isotonic
(320 mOsm) or hypotonic (240 mOsm) solution (as described for
electrophysiology) for 1 h at 37°C. The drug-containing solutions
were then replaced by normal medium and cells incubated for dif-
ferent times. Caspase activity from cytosolic extracts was monitored
fluorometrically in a Safire2 plate reader (Tecan AG, CH) set at 37°C
using as substrate 30 lM Ac-DEVD-AMC (Enzo). Specific enzymatic
activity was calculated from the slopes of the best fit curves and
normalized to total protein. For long-term isotonic protocols, the
activity was further normalized to “time zero” samples.
Measurement of taurine efflux
HEK293 cells were grown to ~80% confluency (48–72 h after plat-
ing) in 35-mm diameter plates coated with poly-L-lysine. For rescue
experiments, cells were transfected one day before flux measure-
ments with an LRRC8D expression plasmid using Fugene HD. WT
and LRRC8D/ control cells were mock transfected with a GFP
expression vector. Cells were loaded with 3[H]-taurine (2 lCi/ml;
Hartmann Analytics) for 2 to 2.5 h in culture medium (without FCS)
at 37°C. They were then washed five times at room temperature
with isotonic solution (same as used in electrophysiology). After
washing, external media were removed in 5-min intervals and
replaced with fresh isotonic or hypotonic solution (same as in elec-
trophysiology) and saved for counting. To measure cisplatin-induced
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taurine efflux, cells were preincubated with cisplatin (200 lM) in
cell culture medium for 2 or 10 h. Cells were then loaded with
3[H]-taurine for 2 h in cell culture medium (200 lM cisplatin, w/o
FCS and w/o DMSO) at 37°C. Cells were washed 5 times and incu-
bated for 30 min at 37°C with fresh isotonic solution. As a control
for LRRC8 contribution to cisplatin-induced taurine efflux, isotonic
solution containing 100 lM carbenoxolone was used throughout
the washes. At the end of the experiments, cells were lysed with
0.75 ml of 0.1 M NaOH. The radioactivity of cell supernatants and
of the final cell lysate was determined in a liquid scintillation
counter. Rate constants were calculated as previously described
(Holm et al, 2013).
Uptake of cisplatin into cells
Intracellular platinum drug concentrations were measured as
described (Brouwers et al, 2005) or by ICP-MS (Brouwers et al,
2006) (NKI and Institut fu¨r Medizinische Diagnostik (IMD), Berlin).
Cells in 6-cm plates (~90% confluency) were incubated at 37°C/5%
CO2 in DMEM/FCS containing cisplatin (without DMSO) for dif-
ferent times as indicated. For determining the dependence of uptake
on osmolarity, cells were incubated with 200 lM cisplatin in
isotonic or hypotonic solution (same as used in electrophysiology)
for the indicated time periods at 37°C. At the end of the uptake
period, cells were quickly washed 5 times with 3 ml ice-cold PBS,
collected, gently spun down (1,000 g, 5 min, 4°C), and the pellet
was resuspended in 0.1 M HCl. For carboplatin uptake in KBM7
cells grown in suspension, 2 × 107 cells per group (in T25 flasks)
were incubated at 37°C/5% CO2 in IMDM Glutamax (10% FBS)
containing 7 lM carboplatin (without DMSO) and samples were
collected at the indicated time points after drug treatment. Cells
were quickly washed twice with 10 ml cold PBS (400 g, 5 min), and
the pellet was resuspended in 1 ml cold PBS. Of this suspension,
100 ll was taken for protein concentration determination using the
BCA assay. The rest (900 ll) was spun down (400 g, 5 min) and
resuspended in 200 ll 0.1 M HCL for ICP-MS.
Statistics
Data are presented as mean  SEM, with n denoting the number of
observations (samples). For RVD measurements (Fig 3C), cisplatin
uptake in Figs 6C–F and EV4, caspase induction (Fig 4A), activation
of VRAC iodide flux (Fig 5), and Western blots (Fig EV1), a mini-
mum of two independent experiments were performed with similar
results. Student’s t-tests for paired or unpaired data were employed
as appropriate and considered as significant as follows: *P < 0.05;
**P < 0.01; and ***P < 0.001.
Gene expression and survival analysis based on published data
concerning ovarian cancer patients
Gene expression data were downloaded from the TCGA
(http://cancergenome.nih.gov/). The expression data are derived
from RNAseq with expression quantification using RSEM. The
density plot shows the log of the gene expression of the individual
LRRC8 family members. The survival analysis uses the clinical data
provided by the TCGA. The number of days to death is scored as an
event. As time interval definition, we used “days_to_last_follow-up.”
This is the time interval from the date of last follow-up to the
date of initial pathologic diagnosis, represented as a calculated
number of days (https://tcga-data.nci.nih.gov/docs/dictionary/).
The patients were stratified on the expression levels of LRRC8A or
LRRC8D. Those that were in the lowest tertile (< 33%) of the levels
were classed as having low expression. The analysis is performed
with the package “survival” from the R-project.
The Australian ovarian cancer (OV AU) expression data of the
study performed by Patch et al (2015) were gene-wise matched to
the TCGA panel after which the selected RSEM was normalized. A
survival analysis was performed contrasting the low (< 33%)
expression of LRRC8A or LRRC8D against the rest.
Expanded View for this article is available online.
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